Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

ite of Origin for GI Carcinoid Tumors 14Table 7:Diagnosis Tests for Different Types of Functioning Pancreatic Neuroendocrine Tumors 15Table 8:TNM Classification of Stomach Carcinoid Tumors 16Table 9:TNM Classification of Duodenum Carcinoid Tumors 17Table 10:TNM Staging of Appendiceal Carcinoid Tumors 17Table 11:TNM Classification of Pancreatic Neuroendocrine Tumors 18Table 12:TNM Staging for Pancreatic Neuroendocrine Tumors 18Table 13:Chemotherapy Regimens in GEP-NETs Carcinoma 22Table 14: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Revenue ($m), 2006–2011 25Table 15: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Market Forecast ($m), 2011-2019 28Table 16:Neuroendocrine Carcinoma Therapeutics Market, the US, Revenue ($m), 2006–2011 29Table 17: Neuroendocrine Carcinoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019 30Table 18:Neuroendocrine Carcinoma Therapeutics Market, the UK, Revenue ($m), 2006–2011 31Table 19: Neuroendocrine Carcinoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019 32Table 20:Neuroendocrine Carcinoma Therapeutics Market, France, Revenue($m), 2006–2011 33Table 21: Neuroendocrine Carcinoma Therapeutics Market, France, Market Forecast ($m), 2011-2019 34Table 22:Neuroendocrine Carcinoma Therapeutics Market,Germany, Revenue ($m), 2006–2011 35Table 23: Neuroendocrine Carcinoma Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 36Table 24:Neuroendocrine Carcinoma Therapeutics Market, Italy, Revenue($m), 2006–2011 37Table 25: Neuroendocrine Carcinoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 38Table 26:Neuroendocrine Carcinoma Therapeutics Market, Spain, Revenue ($m), 2006–2011 39Table 27:Neuroendocrine Carcinoma Therapeutics Market, Spain, Market Forecast ($m), 40Table 28:Neuroendocrine Carcinoma Therapeutics Market, Japan, Revenue ($m), 2006–2011 41Table 29: Neuroendocrine Carcinoma Therapeutics Market, Jap
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Based on the ... surgical imaging market is dominated by four major ... imaging market. These players include GE Healthcare (U.K.), ... (Germany). , Full Report Copy at ... Healthcare can be attributed to its strong product ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... 18 Martek Biosciences,(Nasdaq: MATK ) announced today ... patented, vegetarian form of DHA omega-3 for brain, eye,and ... vegetarian DHA,Oroweat 9 Grain Bread with life,sDHA from Bimbo ... Pacific Northwest, California, Arizona,and Nevada., "This new launch ...
... Baxter,International Inc. (NYSE: BAX ) announced today ... an additional $2 billion of the company,s,common stock to ... authorization., Baxter has less than $700 million of ... that was authorized in March,2007. Shares will be repurchased ...
... Calif., March 18 TorreyPines Therapeutics,Inc. (Nasdaq: ... Phase II study of,NGX267, a muscarinic agonist in ... syndrome., The company is conducting a randomized, ... to evaluate,the safety, tolerability and efficacy of this ...
Cached Biology Technology:Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 2Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 3Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... training video produced by Rafael Ortega, MD, the vice-chair ... Boston Medical Center (BMC) and professor of anesthesiology at ... is featured in this week,s New England Journal ... is the fifth BMC-produced video to appear in the ...
... After 30 years with Chip Supply, Inc., President ... Perrott served in various capacities through the ... tenure, Chip Supply grew into the largest independent die ... global provider of high reliability interconnect solutions, serving the ...
... BUFFALO, NY -- Exposure to air pollution early in life ... may alter her DNA and may be associated with premenopausal ... Buffalo have shown. The findings indicated that higher air ... increase levels of E-cadherin, a protein important to the adhesion ...
Cached Biology News:Pulse oximetry training video by BMC anesthesiologist published in NEJM 2Air pollution exposure affects chances of developing premenopausal breast cancer 2